Investigating the impact of COVID-19 lockdown on adults with a recent history of recurrent major depressive disorder: a multi-centre study using remote measurement technology

Leightley, Daniel, Lavelle, Grace, White, Katie M, Sun, Shaoxiong, Matcham, Faith, Ivan, Alina, Oetzmann, Carolin, Penninx, Brenda W J H, Lamers, Femke, Siddi, Sara, Haro, Josep M, Myin-Germeyns, Inez, Bruce, Stuart, Nica, Raluca and others, (2021) Investigating the impact of COVID-19 lockdown on adults with a recent history of recurrent major depressive disorder: a multi-centre study using remote measurement technology. BMC Psychiatry, 21. a435 1-11. ISSN 1471-244X

This version is available from Sussex Research Online: http://sro.sussex.ac.uk/id/eprint/110985/

This document is made available in accordance with publisher policies and may differ from the published version or from the version of record. If you wish to cite this item you are advised to consult the publisher's version. Please see the URL above for details on accessing the published version.

Copyright and reuse:
Sussex Research Online is a digital repository of the research output of the University.

Copyright and all moral rights to the version of the paper presented here belong to the individual author(s) and/or other copyright owners. To the extent reasonable and practicable, the material made available in SRO has been checked for eligibility before being made available.

Copies of full text items generally can be reproduced, displayed or performed and given to third parties in any format or medium for personal research or study, educational, or not-for-profit purposes without prior permission or charge, provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way.

http://sro.sussex.ac.uk
Investigating the impact of COVID-19 lockdown on adults with a recent history of recurrent major depressive disorder: a multi-Centre study using remote measurement technology

Daniel Leightley 1*, Grace Lavelle 1, Katie M. White 1, Shaoxiong Sun 2, Faith Matcham 1, Alina Ivan 1, Carolin Oetzmann 1, Brenda W. J. H. Pennin 3, Femke Lamers 3, Sara Siddi 4,5,6, Josep Mario Haro 4,5,6, Inez Myin-Germeys 7, Stuart Bruce 8, Raluca Nica 8,9, Alice Wickershams 1, Peter Annas 10, David C. Mohr 11, Sara Simblett 12, Til Wykes 12, Nicholas Cummins 2,13, Amos Akinola Folarin 2,14,15, Pauline Conde 2, Yatharth Ranjan 2, Richard J. B. Dobson 2,16, Viabhav A. Narayan 17, Mathew Hotopf 1,16, and On behalf of the RADAR-CNS Consortium

Abstract

**Background:** The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes a clinical illness Covid-19, has had a major impact on mental health globally. Those diagnosed with major depressive disorder (MDD) may be negatively impacted by the global pandemic due to social isolation, feelings of loneliness or lack of access to care. This study seeks to assess the impact of the 1st lockdown – pre-, during and post – in adults with a recent history of MDD across multiple centres.

**Methods:** This study is a secondary analysis of an on-going cohort study, RADAR-MDD project, a multi-centre study examining the use of remote measurement technology (RMT) in monitoring MDD. Self-reported questionnaire and passive data streams were analysed from participants who had joined the project prior to 1st December 2019 and had completed Patient Health and Self-esteem Questionnaires during the pandemic (n = 252). We used mixed models for repeated measures to estimate trajectories of depressive symptoms, self-esteem, and sleep duration.

**Results:** In our sample of 252 participants, 48% (n = 121) had clinically relevant depressive symptoms shortly before the pandemic. For the sample as a whole, we found no evidence that depressive symptoms or self-esteem changed between pre-, during- and post-lockdown. However, we found evidence that mean sleep duration (in minutes) decreased significantly between during- and post-lockdown (−12.16; 95% CI −18.39 to −5.92; p < 0.001). We also found that those experiencing clinically relevant depressive symptoms shortly before the pandemic showed a decrease in depressive symptoms, self-esteem and sleep duration between pre- and during- lockdown (interaction p = 0.047, p = 0.045 and p < 0.001, respectively) as compared to those who were not.
Conclusions: We identified changes in depressive symptoms and sleep duration over the course of lockdown, some of which varied according to whether participants were experiencing clinically relevant depressive symptoms shortly prior to the pandemic. However, the results of this study suggest that those with MDD do not experience a significant worsening in symptoms during the first months of the Covid-19 pandemic.

Keywords: Remote measurement technology, Major depressive disorder, Mobile health

Background
On the 31st December 2019, the World Health Organisation (WHO) documented reports of a cluster of cases of pneumonia of unknown origin in Wuhan, China [1]. The cause was later identified as a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which caused a clinical illness, Covid-19 [2]. Within weeks of the initial outbreak, the total number of cases and deaths had exceeded those of severe acute respiratory syndrome outbreak in 2003 [3]. In March 2020, a global pandemic was declared by the WHO due to the exponential increase in diagnosed cases and deaths, with countries across Europe implementing national lockdowns to reduce the risk of spread and infection [4].

The ongoing Covid-19 pandemic is predicted to have severe negative global mental health consequences [5, 6], with a review of stressors indicating that quarantine duration, infection fears, frustration, boredom, inadequate information, financial loss, loss of sleep and stigma being the main drivers [7]. The pandemic has disrupted or halted critical mental health services in 93% of countries worldwide, while the demand for mental health care is increasing, according to a recent WHO survey [8]. There have been urgent calls to examine the mental health consequences of Covid-19 at an international level, using high-quality data and robust analysis techniques [9–11].

Gaining a clear indication of population impacts of the pandemic on mental health has been challenging [6]. Pre-existing population studies, which have explicit sampling frames and longitudinal data pre-dating the pandemic, have demonstrated an increase in symptoms of distress within the general population [6, 12]. And in the early stages of the pandemic this was dominated by symptoms of anxiety [12], with symptoms of distress most frequent in young adults [6]. In addition, one population study found sleep to be negatively impacted by the pandemic, with female participants reporting more sleep loss than male participants [13].

A less studied issue has been the impact of public health measures, such as lockdown, on individuals with pre-existing mental disorders who may have less access to care and support services [8]. Adults diagnosed with major depressive disorder (MDD) and experiencing a current episode of depression are particularly susceptible to the challenges raised by lockdown, such as disrupted sleep [14], reduced sociability [15] and changes in mood/self-esteem [16]. Therefore, it is important to understand the trajectories of change in those experiencing a current episode of depression and how these outcomes are impacted by the pandemic.

Across Europe, smartphone ownership and use is high (estimated 76% of adults across Europe [17]), which provides a ready means for accurate and ongoing data collection using remote measurement technology (RMT) [18–20]. RMT data collection methods are inexpensive, can gather data in real-time, and crucially considering infection risk, do not require face-to-face contact between the research team and participants. RMT may provide a solution to the need for surveillance at the population level passively, without the need for intrusive study protocols, or continual engagement. This may lead to richer, more objective and holistic characterisation of behaviours and physiology as a result of the Covid-19 pandemic.

Remote Assessment of Disease and Relapse in individuals with Major Depressive Disorder (RADAR-MDD) is an ongoing study forming a component of the RADAR-Central Nervous System consortium [21]. Participants with MDD from the UK, Spain and The Netherlands were invited to provide longitudinal data via ubiquitous, commercially-available RMT (i.e. phones and activity trackers) [18]. The high-frequency information collected passively includes detail on participants’ sleep quality/patterns, physical activity, stress, mood, self-esteem, sociability, speech patterns, and cognitive function [18]. In addition to passive data collection, self-reported ecological momentary assessment data was also collected. This included assessments focusing on depression, speech, self-esteem, and cognitive function. The study provides an opportunity to explore the impact of the pandemic on individuals with a MDD diagnosis and their changes in depressive symptoms across Europe. A strength of RADAR-CNS is the ability to directly compare results gathered during- and post- lockdown with previously collected pre-lockdown baseline data.

The potential impact of the pandemic on individuals with mental disorders has been recognised as one of a triad of key current global mental health challenges [22]. Relatively high rates of depression have been reported by a number of countries [23], this adding to the existing global burden of depression [24]. However, tackling this in its entirety demands a greater understanding of the
true impact of Covid-19 for those living with pre-existing mental disorders. We therefore aimed to investigate the impact of the 1st global lockdown on adults with a recent history of MDD, through the following objectives: 1) To investigate changes in depressive symptoms, self-esteem and sleep duration pre-, during- and post-lockdown in the period from 1st December 2019 to 1st September 2020; and 2) To investigate whether these changes over time varied according to whether participants were experiencing a depressive episode shortly before the pandemic.

Method
Data source and participants
This study uses data collected between 1st December 2019 and 1st September 2020 (9 months of available data) from the RADAR-MDD project, a multi-centre cohort, examining the use of RMT in monitoring MDD [18]. Participants were required to meet the following eligibility criteria: 1) DSM-5 diagnostic criteria for diagnosis of non-psychotic MDD in the last 2 years, 2) recurrent MDD (lifetime history of at least 2 episodes of depression, 3) willingness and ability to complete self-reported assessment via smartphone, 4) provide informed consent, 5) own an Android smartphone, or willing to use an Android smartphone provided by the research team, 6) aged 18 years or over, and 7) fluent in English, Spanish, Catalan or Dutch. The study protocol for RADAR-MDD has been previously reported [18].

The data collected via RADAR-MDD project uses RADAR-base, which is an open source platform designed to leverage data from wearables and mobile technologies [21]. RADAR-base provides both passive and active data collection via two applications – active and passive. The passive app collects real time monitoring of movement, location, audio and app usage [21]. The active app collects self-reported user questionnaires. Data from both apps are streamed in real-time to project servers. It is important to note that RADAR-base does not provide a feedback loop to the participant or any clinicians.

In total, 623 participants met the eligibility criteria and were recruited between November 2017 and June 2020 across three European countries: United Kingdom (n = 350; 56.2%), Spain (n = 155; 24.9%) and The Netherlands (n = 118; 18.4%). Participants in the UK and The Netherlands were recruited from community samples including individuals from existing studies on depression and using local clinical services. All participants recruited for this study had pre-existing major depressive disorder, and all recruitment sites utilised the same eligibility criteria for entry into the study. The Netherlands also recruited through advertisements in general practices and psychologist practices, newspaper advertisements and through Hersenonderzoek.nl (https://hersenonderzoek.nl). Spanish participants were recruited from a clinical sample of individuals seeking help for a mental health condition.

Each participant was asked to wear a wrist-worn activity tracker (FitBit Charge 2 or 3) and install the active and passive RADAR-base applications onto their smartphones (see [18, 21] for further details). The project was developed using co-design and in partnership with a Patient Advisory Group. Project apps were used to collect data passively from existing smartphone sensors, and to deliver questionnaires, cognitive tasks, and speech assessments. The wrist-worn activity tracker and project apps collected data on participants’ sleep, physical activity, stress, mood, self-esteem, sociability, speech patterns, and cognitive function.

The RADAR-MDD project is currently on-going and final data collection is expected in March 2021. Participants were excluded from the current study if they had withdrawn from the RADAR-MDD project at any time (n = 78; 12.5%), enrolled in RADAR-MDD after the 1st December 2019 (n = 200; 32.1%), had not completed a self-reported Patient Health Questionnaire (PHQ) in December 2019, or were missing basic demographics at baseline (n = 93; 14.9%). A total of 252 (40.5%) participants remained after exclusions and their data was used for analysis.

The RADAR-MDD project received ethical approval in the United Kingdom from the Camberwell St Giles Research Ethics Committee (REC reference: 17/LO/1154); and Spain from the CEIC Fundació Sant Joan de Déu (CI reference: PIC-128-17) and in The Netherlands from the Medische Ethische Toetsingscommissie VUmc (METc VUmc registratienummer: 2018.012 – NL63557.029.17). The research was undertaken in accordance with the Declaration of Helsinki, and all participants provided informed consent to participate.

Measures and features
The RADAR-MDD project collects a range of validated measures from participants at different timepoints (see further [18] information) using the RADAR-base active app [25]. RADAR-base sends automatic survey invitations (email and in-app push notification).

Depressive symptoms
The Patient Health Questionnaire (PHQ-8 [26]) was delivered every 2 weeks via the project app. The PHQ-8 is an 8-item self-report questionnaire which measures the frequency of depressive symptoms over the preceding 2-week period. Each item is rated on a scale of 0–3, producing a range of total scores from 0 to 24. The PHQ-8 has good validity, reliability, sensitivity, and specificity in the general population [26]. In this study, a cut-off score
of 10 or more is defined as a case of clinically relevant depressive symptoms (hereafter ‘depression’) [26].

Self-esteem
The Rosenberg Self-Esteem Scale (RSES [27]) was delivered every 2 weeks via the project app alongside the PHQ-8. The RSES is a 10-item self-report instrument for evaluating individual self-esteem [27–29]. Each item is rated on a scale of 1–3 (half the questions are reverse scored), producing a range of scores from 0 to 30. Scores between 15 and 25 are within normal range, with scores below 15 suggesting low self-esteem [27].

Sleep duration
Participants enrolled in the RADAR-MDD project were asked to wear a wrist-worn activity tracker (FitBit Charge 2 or 3) over the study duration as much as possible, including when sleeping. The device collected parameters on heart rate and sleep duration. In this study, total sleeping minutes, as computed by the FitBit Charge 2 or 3, was extracted for each participant for each day and a daily feature was calculated to represent the amount slept for each 24-h period. Total sleep duration was calculated between 8:00 pm (20:00) as the starting time point and 11:00 am (11:00) as the finishing time point (following a procedure reported previously [30]). Where no data was found due to the participant not wearing the device, no features were computed for that day.

Data analysis
Socio-demographic characteristics were summarised using frequencies and unweighted percentages or medians with interquartile ranges (IQR) for the overall sample and for each country individually. Outcome variables (depressive symptoms, self-esteem and sleep duration) were then summarised across three timepoints: pre-, during- and post-lockdown (defined as restriction easing in each country). A mean value was calculated to represent the amount slept for each 24-h period. Total sleep duration was calculated between 8:00 pm (20:00) as the starting time point and 11:00 am (11:00) as the finishing time point (following a procedure reported previously [30]). Where no data was found due to the participant not wearing the device, no features were computed for that day.

Results
Socio-demographic characteristics at baseline
The majority of the sample was female (n = 188; 74.6%), had clinically relevant depressive symptoms shortly before the pandemic (n = 121, 48.0%), was cohabiting or married (n = 138; 54.8%) and was on medication for management of depression (n = 166; 65.9%) at baseline (see Table 1).

Depressive symptom trajectories
Overall, mean depressive symptoms remained stable between pre- and during-lockdown (estimated mean score difference: -0.18; CI: -0.61 to 0.24, p = 0.339) and between during- and post-lockdown (estimated mean score difference: -0.03; CI: -0.42 to 0.36, p = 0.882) (Table 2). We then added an interaction term between depression caseness and timepoint to investigate whether these trajectories varied according to depression caseness.
Table 1: Cohort characteristics at baseline (n = 252) stratified by country

| Variable                              | Overall (n = 252) | United Kingdom (n = 140; 55.6%) | Spain (n = 70; 27.8%) | The Netherlands (n = 42; 16.7%) |
|---------------------------------------|-------------------|--------------------------------|-----------------------|--------------------------------|
| Sex                                   |                   |                                |                       |                                |
| Male                                  | 64 (25.4)         | 30 (21.3)                      | 24 (34.3)             | 10 (23.8)                      |
| Female                                | 188 (74.6)        | 110 (78.6)                     | 46 (65.7)             | 32 (76.2)                      |
| Marital status                        |                   |                                |                       |                                |
| Single                                | 75 (29.8)         | 40 (28.6)                      | 10 (14.3)             | 25 (59.5)                      |
| Married/cohabiting                    | 138 (54.8)        | 82 (58.6)                      | 43 (61.4)             | 13 (30.9)                      |
| Divorced/Separated/Widowed            | 39 (15.5)         | 18 (12.9)                      | 17 (24.3)             | 4 (9.5)                        |
| Employment                            |                   |                                |                       |                                |
| Employed                              | 115 (45.6)        | 66 (47.1)                      | 28 (40.0)             | 21 (50.0)                      |
| Retired                               | 64 (25.4)         | 35 (25.0)                      | 25 (35.7)             | 4 (9.5)                        |
| Student                               | 23 (9.1)          | 12 (8.8)                       | 1 (1.4)               | 10 (23.8)                      |
| Unemployed                            | 26 (10.3)         | 14 (10.0)                      | 9 (12.9)              | 3 (7.1)                        |
| Other                                 | 24 (9.5)          | 13 (9.3)                       | 7 (10.0)              | 4 (9.5)                        |
| Age (in years)                        |                   |                                |                       |                                |
| < 25                                  | 16 (6.4)          | 7 (5.0)                        | –                     | 9 (21.4)                       |
| 25–34                                 | 35 (13.9)         | 22 (15.7)                      | 2 (2.9)               | 11 (26.2)                      |
| 35–44                                 | 38 (15.1)         | 22 (15.7)                      | 12 (17.1)             | 4 (9.5)                        |
| 45–54                                 | 42 (16.7)         | 19 (13.6)                      | 18 (25.7)             | 5 (11.9)                       |
| 55–64                                 | 81 (32.2)         | 44 (31.4)                      | 28 (40.0)             | 9 (21.4)                       |
| 65>                                   | 40 (15.9)         | 26 (18.6)                      | 10 (14.3)             | 4 (9.5)                        |
| Medication for Depression             |                   |                                |                       |                                |
| No                                    | 48 (19.1)         | 36 (25.7)                      | 2 (2.9)               | 10 (23.8)                      |
| Yes                                   | 166 (65.9)        | 80 (57.1)                      | 65 (92.9)             | 21 (50.0)                      |
| Not reported                          | 38 (15.1)         | 24 (17.1)                      | 3 (4.3)               | 11 (26.2)                      |
| Depression* (December 2019)           |                   |                                |                       |                                |
| No Depression                         | 131 (52.0)        | 87 (62.1)                      | 28 (40.0)             | 16 (38.10)                     |
| Depression                            | 121 (48.0)        | 53 (37.9)                      | 42 (60.0)             | 26 (61.9)                      |
| Length of education (in years) (mean, SD)b| 15.9 (6.5)        | 16.5 (5.5)                     | 12.5 (4.9)            | 19.3 (8.9)                     |
| Length of time in study in days [median, IQR]b| 253 (124 to 327) | 285.5 (186.5 to 435)          | 257.5 (158 to 306)    | 109.5 (44 to 170)              |

*aAs measured by the Patient Health Questionnaire [26]. Depression defined as scoring 10 or more. bUp to 1st December 2019

Table 2: Estimated overall differences in each outcome variable between each timepoint. Results stratified by country are available from the corresponding author.

| Variable                              | Estimated difference between pre- and during- lockdown (95% CI, p-value) | Estimated difference between during- and post- lockdown (95% CI, p-value) |
|---------------------------------------|------------------------------------------------------------------------|------------------------------------------------------------------------|
| Mean PHQ-8 score                      | -0.18 (−0.61 to 0.24; p = 0.339)                                       | -0.03 (−0.42 to 0.36; p = 0.882)                                       |
| Mean RSES score                       | -0.06 (−0.22 to 0.10; p = 0.445)                                       | 0.07 (−0.08 to 0.22; p = 0.381)                                       |
| Mean sleep duration                   | -0.01 (−5.55 to 5.56; p = 1.000)                                       | -12.16 (−18.39 to −5.92; p < 0.001)                                   |
Perhaps unsurprisingly, those with pre-pandemic depression reported more depressive symptoms at all three timepoints (Table 3). However, there was also some evidence for an interaction between depression caseness and timepoint in predicting course of depressive symptoms between pre- and during-lockdown ($p = 0.047$; Table 3).

We further investigated this using post-estimation commands and found very weak evidence that the depressed group showed a decrease in depressive symptoms between pre- and during-lockdown (estimated mean score: $-0.61$; CI: $-1.23$ to $0.01$; $p = 0.051$), whereas the non-depressed group remained stable (estimated mean score: $0.24$; CI: $-0.33$ to $0.83$, $p = 0.409$) (Fig. 1).

Self-esteem trajectories
Overall, mean self-esteem score remained stable between pre- and during-lockdown (estimated mean score difference: $-0.06$; CI: $-0.22$ to $0.10$, $p = 0.445$) and between during- and post-lockdown (estimated mean score difference: $0.07$; CI: $-0.08$ to $0.22$, $p = 0.381$) (Table 2).

We then added an interaction term between depression caseness and timepoint to investigate whether these trajectories varied according to depression caseness. Those with pre-pandemic depression reported lower self-esteem scores throughout the pandemic than those without depression (Table 3). There was also some evidence for an interaction between depression caseness and timepoint in predicting course of self-esteem between pre- and during-lockdown ($p = 0.045$; Table 3).

We further investigated this using post-estimation commands and found evidence that the depressed group showed reducing self-esteem scores between pre- and during-lockdown (estimated mean score: $-0.24$; CI: $-0.47$ to $0.01$; $p = 0.048$), whereas the non-depressed group remained stable (estimated mean score: $0.09$; CI: $-0.13$ to $0.32$, $p = 0.409$) (Fig. 2).

Sleep duration trajectories
Overall, mean sleep duration remained stable between pre- and during-lockdown (estimated mean duration difference: $-0.01$; CI: $5.55$ to $5.56$, $p = 1.000$). However, between during- and post-lockdown there was evidence of a significant decrease in mean sleep duration (estimated mean duration difference: $-12.16$; CI: $-18.39$ to $-5.92$, $p < 0.001$) (Table 2).

We then added an interaction term between depression caseness and timepoint to investigate whether these trajectories varied according to depression caseness. Those with pre-pandemic depression reported shorter sleep durations during- and post-lockdown relative to those without (Table 3). There was also evidence for an interaction between depression caseness and timepoint

Table 3 Estimated difference in each outcome variable between no depression and depression (in December 2019) at each timepoint, and differences in rate of change over time. Results stratified by country are available from the corresponding author.

|                | Pre-lockdown estimate | During-lockdown estimate | Post-lockdown estimate | Evidence for a difference in the rate of change between pre- and during-lockdown. (Interaction p-value) | Evidence for a difference in the rate of change between during- and post-lockdown. (Interaction p-value) |
|----------------|-----------------------|--------------------------|------------------------|-----------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------|
| $n = 252$      |                        |                          |                        |                                                                                                     |                                                                                                    |
| No Depression  | Reference group        | –                        | –                      | –                                                                                                    | –                                                                                                   |
| Depression     | 9.33 (8.32 to 10.34)   | 8.47 (7.21 to 9.73)      | 7.83 (6.70 to 8.96)    | 0.047                                                                                               | 0.112                                                                                               |
| $n = 252$      |                        |                          |                        |                                                                                                     |                                                                                                    |
| No Depression  | Reference group        | –                        | –                      | –                                                                                                    | –                                                                                                   |
| Depression     | −1.09 (−1.46 to −0.72) | −1.43 (−1.85 to −1.05)   | −1.31 (−1.69 to −0.92) | 0.045                                                                                               | 0.461                                                                                               |
| $n = 240$      |                        |                          |                        |                                                                                                     |                                                                                                    |
| No Depression  | Reference group        | –                        | –                      | –                                                                                                    | –                                                                                                   |
| Depression     | −10.48 (−28.38 to 7.41)| −32.98 (−53.32 to 12.64) | −28.26 (−50.67 to −5.85)| < 0.001                                                                                             | 0.458                                                                                               |
in predicting course of mean sleep duration between pre- and during-lockdown ($p < 0.001$; Table 3).

We further investigated this using post-estimation commands and found strong evidence that the depressed group showed significant decreases in mean sleep duration between pre- and during-lockdown (estimated mean duration difference: $-11.64$; CI: $-19.33$ to $-3.95$; $p = 0.003$), whereas the non-depressed group significantly increased mean sleep duration (estimated mean sleep duration difference: $10.85$; CI: $3.43$ to $18.27$; $p = 0.004$) (Fig. 3). However, the interaction between depression caseness and timepoint between during- and post-lockdown was not statistically significant, suggesting that both depression and no depression groups showed a similar rate of decline in sleep duration between these timepoints.

**Discussion**

In this study, we investigated the depressive symptom trajectories for a cohort of adults with a recent history of
MDD. For the sample as a whole, we found no evidence that depressive symptoms or self-esteem changed over the course of lockdown. However, we found evidence that mean sleep duration decreased between during- and post-lockdown. We also found that, relative to those who did not show evidence of clinically relevant depressive symptom severity shortly before the pandemic, those with pre-pandemic depression showed a significant decrease in sleep duration (in minutes) between pre- and during-lockdown. However, while there were also reductions in symptom and self-esteem scores, this reduction was not clinically meaningful.

The Covid-19 pandemic represents a unique health, social and economic challenge, with the impact on global mental health expected to be high [33], the use of RMT to explore a pre-existing MDD cohort has provided unique insights into behaviours over the duration of the pandemic. The rapid spread and persistence of Covid-19 has increased health anxieties, and has resulted in an increase in mental health disorders globally [34]. In our study, we focused on a less studied area, those with pre-existing MDD, which has been shown to be negatively impacted as a result of the Covid-19 pandemic, with the severity varying based on occupation, gender, geographical location and physical/mental health comorbidities [33, 35, 36]. There are major differences in the prevalence of depression globally, with one US cohort identifying a three-fold increase in depression symptoms during the pandemic than before [35]. This contrasts a Dutch study, which found that while those with depression scored highly on symptom scales, they did not report greater increases in symptoms during the pandemic [37].

Our overall findings are similar to those reported in The Netherlands, while overall depression score changed compared with a period just before the pandemic, the change was not clinically meaningful and suggests participants depression remained stable. It is important to acknowledge that lockdown restrictions could have moderated depression symptom change, with varying levels of restrictions imposed across the UK, The Netherlands and Spain. In addition, our findings could be explained as regression to the mean, or improvements in depression over time due to the cyclic nature of the disorder.

Sufficient sleep is essential for cognitive and psychological functioning, and prior research has shown that poor quality sleep is associated with depression and longer term health outcomes [38–40]. Using data collected via a wearable device and RMT, we found that trajectories of sleep duration decreased significantly pre-, during- and post-lockdown in the depressed group with evidence of an interaction between pre- and during-lockdown. This reduction in sleep, and persistence to post-lockdown could indicate an adverse impact of the pandemic and requires further investigation to assess its impact on clinical outcomes. An alternative theory could be that reduced activity levels could result in less sleep being required, and not, therefore, detrimental but merely an adjustment in how much sleep is needed. It must be acknowledged that prior research has indicated that FitBit devices underestimate sleep onset, which could have impacted our results [41].
Self-esteem is an important indicator of self-worth. When a participant has healthy self-esteem, they tend to feel positive about themselves, and about life in general. Conversely, when self-esteem is low, participants tend to see themselves and life in a more negative and critical light [27, 29, 42]. In this study, we found that there were differences in self-esteem across timepoints, with small but not clinically meaningful changes between pre- and during-lockdown. This could suggest an overall small change in the outlook of participants with pre-pandemic depression.

Our study demonstrates the utility of RMT and wearable technology to evaluate the impact of Covid–19. The potential to gather high-frequency information via wearable technology and smartphones using platforms such RADAR-MDD project has advantages over momentary data capture currently employed in a clinical setting, which often presents in the form of infrequent questionnaires. The capacity of RMT to offer passive monitoring, without the need for active participant engagement, allows longitudinal assessment of more objectively collected outcomes as well as the capacity to offer multi-parametric monitoring. The results of this work enhance our understanding of the impact of lockdown due to Covid–19 for those with MDD as monitored through RMT.

The Covid-19 pandemic presents a unique opportunity for deploying RMT to track disease progression or relapse in symptoms, despite the global lockdown and frequent local restrictions. This work demonstrates the application of large-scale multi-parametric monitoring, gathered at an incomparable frequency to once-off clinic visits, providing real-time data on the effects of Covid-19 for those with MDD and their environment. The unique strength of this work is the ability to directly compare results gathered during- and post-lockdown with previously collated shortly before the start of the pandemic. Many studies rely on participant recall of pre-pandemic health and well-being statuses for comparison purposes. The nature of this study avoids potential recall bias, in addition to the fact that symptom changes are tracked at a high frequency and responses are submitted in real-time via a phone application. The original study aims were not related to Covid–19, and participants included in these analyses joined before December 2019, which allows for the elimination of lockdown bias; participants were not motivated to take part simply on the basis of being personally affected by the pandemic.

Nevertheless some limitations, our study does have some limitations. First, technical issues with mobile devices and RMT apps could have impacted data collection and have contributed to missing data. In addition, participant adherence to the study protocol (i.e. questionnaire completions) decreases over time which further contributes to missing data. While it is difficult to overcome these issues, it is more reflective of real-world data collection and future work will explore if missing data, in itself, is an informative indicator of the participant’s current state. In addition, the pandemic has placed unique stressors on individuals which may have further contributed to data completes. For example, some participants may have been more adherent to the RADAR-MDD project due to fewer life distractions, whereas in some life could have become very difficult resulting in less adherence. Future research should seek to explore this further. Second, RADAR-MDD project used a range of recruitment strategies across the different sites including self-enrolment registers and clinical services, therefore the sample is not necessarily representative of the wider population with MDD. Third, when assessing sleep duration, this study only considered those who slept during the night and not those who had daytime sleep duration. Further work should be undertaken to explore differences between daytime sleep and nighttime sleep duration.

Global healthcare systems face unprecedented challenges in meeting the unmet mental health need. The effects of this pandemic will undoubtedly have far-reaching consequences, with potential long and short-term psychological impacts. However, the results of this study suggest that those with MDD do not experience a significant worsening in symptoms during the first months of the Covid–19 pandemic. Future work should attempt to examine the association between individual socio-demographic characteristics and changes in the examined variables, notable prior to the pandemic and within an individual, to further unpick the impact on those with MDD.

Abbreviations
IQR: Interquartile Range; MDD: Major Depressive Disorder; PHQ8: Patient Health Questionnaire; RADAR-MDD: Remote Assessment of Disease and Relapse in individuals with Major Depressive Disorder; RMT: Remote Measurement Technology; RSES: Rosenberg Self Esteem Scale; SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2; WHO: World Health Organisation

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12888-021-03434-5.

Additional file 1: Supplement A: Missing Data

Acknowledgments
Participant recruitment in Amsterdam was partially accomplished through Hersenonderzoek.nl, a Dutch online registry that facilitates participant recruitment for neuroscience studies (https://hersenonderzoek.nl/). Hersenonderzoek.nl is funded by ZonMw-Memorabel (project no. 7330505003), a project in the context of the Dutch Deltaplan Dementie, Gieskes-Strijbis Foundation, the Alzheimer’s Society in the Netherlands and Brain Foundation Netherlands. Participants from Spain were recruited from 4 clinical network services: Parc Sanitari Sant Joan de Déu Network services,
Institut Català de la Salut, Institut Pere Mata Hospital Clínic San Carlos. This paper represents independent research part funded by the National Institute for Health Research (NIHR) Biomedical Research Centre and South London and Maudsley NHS Foundation Trust and King’s College London. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.

Authors’ contributions
DL wrote the manuscript, undertook data analysis, and data interpretation. GL has contributed to the design of the study and coordination of the study in London. KW has contributed to participant recruitment and the design of the study. SS has contributed to data analysis and data interpretation. FM has contributed to the design of the study and coordination of the study in London. AI has contributed to participant recruitment. CO has contributed to participant recruitment. PB has contributed to participant recruitment, study design and project management. FL has contributed to participant recruitment, study design and project management. SSidi has contributed to participant recruitment. JMH has contributed to participant recruitment, study design and project management. IM has contributed to participant recruitment, study design and project management. SR has contributed to study design and is a participant advisor. RN has contributed to study design and is a participant advisor. AW contributed to data analysis. PA has contributed to participant recruitment, study design and project management. DCM has contributed to study design. Sämblett has contributed to participant recruitment, study design and project management. TW has contributed to participant recruitment, study design and project management. NC has contributed to participant recruitment, study design and project management. AAF has contributed to the development of the RADAR-BASE system used for data collection and management across all sites, data protection, security and storage systems, and contributed to the manuscript. PC has contributed to the development of the RADAR-BASE system used for data collection and management across all sites, data protection, security and storage systems, and contributed to the manuscript. RF has contributed to the development of the RADAR-BASE system used for data collection and management across all sites, data protection, security and storage systems, and contributed to the manuscript. RD has contributed to the development of the RADAR-BASE system used for data collection and management across all sites, data protection, security and storage systems, and contributed to the manuscript. RN has contributed to the design of the study and reviewing the manuscript. MH has contributed to the design of the study and reviewing the manuscript. All authors have all been involved in reviewing the manuscript and have given approval for the it to be published. All authors have agreed to be accountable for all aspects of the work, ensuring that questions relating to the accuracy or the integrity of any part of the work are appropriately investigated and resolved.

Funding
The RADAR-CNS project (www.radar-cns.org) has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115902. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA (www.efpia.eu). This communication reflects the views of the RADAR-CNS consortium and neither IM nor the European Union and EFPIA are liable for any use that may be made of the information contained herein. The funding body have not been involved in the design of the study, the collection or analysis of data, or the interpretation of data.

Availability of data and materials
The datasets generated and/or analysed during the current study are not publicly available due to on-going data collection but are available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
The RADAR-MDD project received ethical approval in the United Kingdom from the Cambrenwell St Giles Research Ethics Committee (REC reference: 17/ LO/1154), and Spain from the CEIC Fundación Sant Joan de Déu (CI reference: PIC-128-17) and in The Netherlands from the Medische Ethische Toetsingscommissie VUMc (METC VUMc registratienummer: 2018.012 – NL63557.029.17). The research was undertaken in accordance with the Declaration of Helsinki, and all participants provided informed consent to participate.

Consent for publication
Not applicable.

Competing interests
WHP has received (non-related) research grants from Janssen Research and Boehringer Ingelheim. DCM has received consulting fees and honoraria from Apple Inc., Otsuka Pharmaceuticals, Pear Therapeutics. Has ownership interest in Adaptive Health, Inc.

Author details
1Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK. 2Department of Biostatistics and Health Informatics, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK. 3Department of Psychiatry, Amsterdam UMC, Vrije Universiteit, Amsterdam, The Netherlands. 4Parc Sanitari Sant Joan de Déu, Fundació Sant Joan de Déu, Barcelona, Spain. 5Universitat de Barcelona, Barcelona, Spain. 6Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Madrid, Spain. 7Center for Contextual Psychiatry, Department of Neurosciences, KU Leuven, Leuven, Belgium. 8RADAR-CNS Patient Advisory Board, King’s College London, London, UK. 9Romanian League for Mental Health, London, UK. 10H Lundbeck A/S, Copenhagen, Denmark. 11Center for Behavioral Intervention Technologies, Northwestern University, Chicago, USA. 12King’s College London, Institute of Psychiatry, Psychology & Neuroscience, London, UK. 13Chair of Embedded Intelligence for Health Care & Wellbeing, University of Augsburg, Augsburg, Germany. 14South London and Maudsley NHS Foundation Trust, London, UK. 15Institute of Health Informatics, University College London, London, UK. 16Maudsley Biomedical Research Centre, National Institute for Health Research, South London and Maudsley NHS Foundation Trust, London, UK. 17Janssen Research and Development, LLC, Titusville, NJ, USA.

Received: 20 March 2021 Accepted: 17 August 2021
Published online: 06 September 2021

References
1. 2019 Novel Coronavirus (2019-nCoV): Strategic preparedness and response plan [Internet]. Geneva, Switzerland; 2020. Available from: https://www.who.int/publications/i/item/strategic-preparedness-and-response-plan-for-the-new-coronavirus.
2. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med [internet]. 2020; 382(8):727–33 Available from: http://www.ncbi.nlm.nih.gov/pubmed/3197945.
3. Petersen E, Koopmans M, Go U, Hamer DH, Petrosillo N, Castelli F, et al. Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics. Lancet Infect Dis [Internet]. 2020;20(9):e238–44 Available from: https://linkinghub.elsevier.com/retrieve/pii/S1473309920304846.
4. Ghebreyesus TA. WHO director-General’s opening remarks at the media briefing on COVID-19 - 11 may 2020 [internet]. 2020. Available from: https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-a t-the-media-briefing-on-covid-19–11-may-2020.
5. Hotopf M, Bullmore E, O’Connor RC, Holmes EA. The scope of mental health research during the COVID-19 pandemic and its aftermath. Br J Psychiatry. 2020;217(4):540–2.
6. Pierce M, Hope H, Ford T, Hatch S, Hotopf M, John A, et al. Mental health before and during the COVID-19 pandemic: a longitudinal probability sample survey of the UK population. Lancet Psychiatry. 2020;7(10):883–92.
7. Brooks SK, Webster RK, Smith LE, Woodland L, Wessely S, Greenberg N, et al. The psychological impact of quarantine and how to reduce it: rapid review of the evidence. Lancet. 2020;395(10227):912–20.
8. Brunier A. COVID-19 disrupting mental health services in most countries, WHO survey [Internet]. World Health Organization. 2020 [cited 2021 Aug 27]. Available from: https://www.who.int/news/item/05-10-2020-covid-19-disrupting-mental-health-services-in-most-countries-who-survey.
9. Holmes EA, O’Connor RC, Perry VH, Tracey I, Wessely S, Arseneault L, et al. Multidisciplinary research priorities for the COVID-19 pandemic: a call for action for mental health science. Lancet Psychiatry. 2020 Jun;7(6):547–60.

10. Xiang Y-T, Yang Y, Li W, Zhang L, Zhang Q, Cheung J, et al. Timely mental health care for the 2019 novel coronavirus outbreak is urgently needed. Lancet Psychiatry. 2020;7(3):228–9.

11. Vindegaard N, Benros ME. COVID-19 pandemic and mental health consequences: systematic review of the current evidence. Brain Behav Immun. 2020;89:531–42.

12. Kwong ASF, Pearson RM, Adams MJ, Northstone K, Tilling K, Smith D, et al. Mental health before and during the COVID-19 pandemic in two longitudinal UK population cohorts. Br J Psychiatry. 2021;218(6):334–43.

13. Falkingham J, Evandrou M, Qin M, Vachantoni A. “Sleepless in Lockdown”: Unpacking Differences in Sleep Loss During the Coronavirus Pandemic in the UK. SSRN Electron. J. 2020.

14. Li S, Chan J, Lam J, Yu M, Wing Y. Can nocturnal sleep disturbances predict non-remission and relapse in patients with major depressive disorder? A 5-year naturalistic longitudinal study. Sleep Med. 2013;14:e48.

15. Shallcross AJ, Gross JJ, Visvanathan PD, Kumar N, Palfrey A, Ford BQ, et al. Relapse prevention in major depressive disorder: mindfulness-based cognitive therapy versus an active control condition. J Consult Clin Psychol. 2015;83(5):964–75.

16. van Rijnbergen GD, Bockting CLH, Burger H, Spinhoff P, Koeter MWJ, Ruhé HG, et al. Mood reactivity rather than cognitive reactivity is predictive of depressive relapse: a randomized study with 5.5-year follow-up. J Consult Clin Psychol. 2013;81(3):508–17.

17. The Mobile Economy Europe [Internet]. 2021 [cited 2021 Feb 22]. Available from: https://www.gsma.com/mobileeconomy/europe/.

18. Matcham F, Barattieri di San Pietro C, Bulgari V, de Girolamo G, Dobson R, Erikson H, et al. Remote assessment of disease and relapse in major depressive disorder (RADAR-MDCS): a multi-centre prospective cohort study protocol. BMC Psychiatry. 2019;19(1):72.

19. Velpulipillai S, Hadlackzcy G, Baca-Garcia E, Gorrell GM, Werbeloff N, Nguyen D, et al. Risk assessment tools and data-driven approaches for predicting and preventing suicidal behavior. Front Psychiatry. 2019;10:36.

20. Wickersham A, Petrides PM, Williamon V, Leighdley D. Efficacy of mobile application interventions for the treatment of post-traumatic stress disorder: a systematic review. Digit Heal. 2019;5:205520761984298.

21. Ranjan Y, Rashid Z, Stewart C, Conde P, Begale M, Verbeeck D, et al. RADAR: open source Mobile health platform for collecting, monitoring, and analyzing data using sensors, wearable, and Mobile devices. JMIR mHealth uHealth. 2019;7(8):e11734.

22. Campion J, Javed A, Sartorius N, Marmot M. Addressing the public mental health challenge of COVID-19. Lancet Psychiatry. 2020;7(8):657–9.

23. Xiong J, Lipitzs O, Nasiri F, Liu LMW, Gill H, Phan L, et al. Impact of COVID-19 pandemic on mental health in the general population: a systematic review. J Affect Disord. 2020;277:55–64.

24. Liu Q, He H, Yang J, Feng X, Zhao F, Lyu J. Changes in the global burden of depression from 1990 to 2017: findings from the global burden of disease study. J Psychiatr Res. 2020;128:34–40.

25. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377–81.

26. Koczewski K, Strine TW, Spitzer RL, Williams JBW, Berry JT, Mokdad AH. The PHQ-8 as a measure of current depression in the general population. J Affect Disord. 2009;114(1–3):163–73.

27. Greenberger E, Chen C, Dmitrieva J, Farrugia SP. Item-wording and the dimensionality of the Rosenberg self-esteem scale: do they matter? Pers Individ Dif. 2003;35(6):1241–54.

28. Sinclair SJ, Blais MA, Ganstler DA, Sandberg E, Bisti K, LoCicero A. Psychometric properties of the Rosenberg self-esteem scale: overall and across demographic groups living within the United States. Eval Health Prof. 2010;33(1):56–80.

29. Elemenjo JS, Courtney BE. The dimensionality of self-esteem: II. Hierarchical facet model for revised measurement scales. J Pers Soc Psychol. 1984;46(2):404–21.

30. Sun S, Folario AA, Ranjan Y, Rashid Z, Conde P, Stewart C, et al. Using smartphones and wearable devices to monitor behavioral changes during COVID-19. J Med Internet Res. 2020;22(9):e19992.

31. Kantis C, Kiernan S, Bardi Socrates J. Timeline of the Coronavirus [Internet]. Think Global Health. 2020 [cited 2020 Jun 21]. Available from: https://www.thinkglobalhealth.org/article/updated-timeline-coronavirus

32. Detry MA, Ma Y. Analyzing Repeated Measurements Using Mixed Models. JAMA [Internet]. 2016;315(4):407 Available from: http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.2015.19394.

33. Bueno-Notivol J, García-García P, Olaya B, Lasheras I, López-Antón R, Santabárbara J. Prevalence of depression during the COVID-19 outbreak: a meta-analysis of community-based studies. Int J Clin Heal Psychol. 2020; 21(1):100196.

34. Salari N, Hosseini-Far A, Jalali R, Vasi-Raygani A, Rasoulipoor S, Mohammadi M, et al. Prevalence of stress, anxiety, depression among the general population during the COVID-19 pandemic: a systematic review and meta-analysis. Glob Health. 2020;16(1):57.

35. Ettmann CK, Abdalla SM, Cohen GH, Sampson L, Vivier PM, Gálea S. Prevalence of depression symptoms in US adults before and during the COVID-19 pandemic. JAMA Netw Open. 2020;3(6):e2019688.

36. Wickersham A, Carr E, Hunt R, Davis JI, Hotopf M, Fear NT, et al. Changes in Physical Activity among United Kingdom University Students: Following the Implementation of Coronavirus Lockdown Measures. Int J Environ Res Public Health [Internet]. 2021;18(6):2792 Available from: https://www.mdpi.com/1660-4601/18/6/2792.

37. Pan K-Y, Kok AAL, Ekelienboom M, Horstfall M, Jörg F, Luteijn RA, et al. The mental health impact of the COVID-19 pandemic on people with and without depressive, anxiety, or obsessive-compulsive disorders: a longitudinal study of three Dutch case-control cohorts. Lancet Psychiatry. 2021;8(2):121–9.

38. Majumdar P, Biswas A, Sahu S. COVID-19 pandemic and lockdown: cause of sleep disruption, depression, somatic pain, and increased screen exposure of office workers and students of India. Chronobiol Int. 2020;37(8):1191–200.

39. Morelli S, Castelnuovo A, Somma A, Castronovo V, Mombelli S, Bottoni D, et al. Impact of COVID-19 lockdown on sleep quality in university students and administration staff. J Neurol. 2021;268(1):18–35.

40. Cellini N, Canale N, Mioni G, Costa S. Changes in sleep pattern, sense of time and digital media use during COVID-19 lockdown in Italy. J Sleep Res. 2020;29(4):e13074.

41. Liang Z, Chapa-Martelli MA. Accuracy of Fitbit wristbands in measuring sleep stage transitions and the effect of user-specific factors. JMIR mHealth uHealth. 2019;7(6):e13384.

42. Ortiz U, Robbins RW. Understanding the link between low self-esteem and depression. Curr Dir Psychol Sci. 2013;22(6):455–60.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.